What Happened?
A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada.
The wider market sentiment turned negative after the White House announced plans to impose a 35% tariff on Canadian imports, sparking renewed fears of a trade war. This news prompted a sell-off across major U.S. indexes, including the S&P 500 and the Dow Jones Industrial Average, as investors grew concerned about the potential economic impact of escalating protectionist policies. The healthcare sector is especially vulnerable to such tensions due to its deeply integrated supply chains with Canada for pharmaceuticals and medical devices, meaning increased costs and potential disruptions.
Additionally, ongoing U.S. policy headwinds aimed at lowering drug prices and specific corporate challenges, like those faced by UnitedHealth Group, further compounded the sector's decline. As a result, the Health Care SPDR ETF (XLV) fell 1.0%, underperforming even as major indices pared some losses.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks.
Among others, the following stocks were impacted:
- Testing & Diagnostics Services company Guardant Health (NASDAQ:GH) fell 3.2%. Is now the time to buy Guardant Health? Access our full analysis report here, it’s free.
- Therapeutics company Gilead Sciences (NASDAQ:GILD) fell 3.7%. Is now the time to buy Gilead Sciences? Access our full analysis report here, it’s free.
- Medical Devices & Supplies - Specialty company Inspire Medical Systems (NYSE:INSP) fell 4.7%. Is now the time to buy Inspire Medical Systems? Access our full analysis report here, it’s free.
- Medical Devices & Supplies - Specialty company Enovis (NYSE:ENOV) fell 4.9%. Is now the time to buy Enovis? Access our full analysis report here, it’s free.
- Specialized Medical & Nursing Services company AMN Healthcare Services (NYSE:AMN) fell 3.2%. Is now the time to buy AMN Healthcare Services? Access our full analysis report here, it’s free.
Zooming In On Enovis (ENOV)
Enovis’s shares are quite volatile and have had 18 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
Enovis is down 22.9% since the beginning of the year, and at $34.15 per share, it is trading 30.8% below its 52-week high of $49.33 from December 2024. Investors who bought $1,000 worth of Enovis’s shares 5 years ago would now be looking at an investment worth $401.24.
Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.